SD BIOSENSOR INC.
Financials
Valuation Metrics
SD BIOSENSOR INC.'s Market Cap is ₩7426B. At end of 2025 it was ₩1.1T. Ranked #363 of 2,421 in KR market (top 15%), #249 of 781 on KOSPI (top 32%), #8 of 96 in Health Care Equipment & Services (top 8%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 742.61B KRW | KR#363/2,421 Sec#8/96 |
| Revenue | 738.76B KRW | KR#491/2,421 Sec#4/96 |
| Net Income | -731.09B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 2.90T KRW | KR#245/2,421 Sec#1/96 |
| Net Assets | 2.41T KRW | KR#159/2,421 Sec#1/96 |
| Employees | 613 | KR#408/2,421 Sec#6/96 |
| Value | ||
| P/B | 0.31x | KR#343/2,421 Sec#3/96 |
| P/S | 1.01x | KR#1,397/2,421 Sec#28/96 |
| FCF Yield | 40.46% | KR#119/2,421 Sec#2/96 |
| Profitability | ||
| ROE | -30.39% | KR#2,184/2,421 Sec#78/96 |
| ROA | -25.20% | KR#2,282/2,421 Sec#85/96 |
| Op. Margin | -8.75% | KR#1,966/2,421 Sec#62/96 |
| Revenue Growth | 5.15% | KR#1,188/2,421 Sec#64/96 |
| Earnings Growth | -489.33% | KR#1,301/2,421 Sec#47/96 |
| Financial Health | ||
| Debt Ratio | 20.61% | KR#382/2,421 Sec#21/96 |
| Total Debt | 536.85B KRW | KR#292/2,421 Sec#2/96 |
| FCF | 300.43B KRW | KR#88/2,421 Sec#1/96 |
| Cash | 230.22B KRW | KR#235/2,421 Sec#2/96 |
| Current Ratio | 6.51x | KR#189/2,421 Sec#17/96 |
| Dividend | ||
| Div. Yield | 3.35% | KR#566/2,421 Sec#8/96 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -39.88% | KR#1,826/2,421 Sec#58/96 |
| 1M Return | 3.02% | KR#920/2,421 Sec#26/96 |
| From 52W High | -43.73% | KR#1,092/2,421 Sec#34/96 |
| 1Y MDD | -46.31% | KR#823/2,421 Sec#25/96 |
| Trading | ||
| Volume | 67,617 shares | KR#977/2,421 Sec#35/96 |
| Trading Value | 417.9M KRW | KR#998/2,421 Sec#33/96 |
| Foreign Own. | 5.97% | KR#733/2,421 Sec#23/96 |
| Per Share | ||
| EPS | -6,055 KRW | KR—/2,421 Sec—/96 |
| BPS | 19,924 KRW | KR#539/2,421 Sec#6/96 |
Company Info
SD BIOSENSOR, established in 2010 as a spin-off from SD Co., Ltd.'s biosensor division, is a mid-sized company as of 2024. The company primarily focuses on R&D and sales of in-vitro diagnostics, including immunochemistry, molecular, point-of-care, and self-blood glucose monitoring. SD BIOSENSOR is expanding its global market and portfolio through a network of over 100 exclusive dealers, direct sales in key countries, and quality competitiveness, including WHO PQ approval. Headquartered in Suwon, Gyeonggi-do, it was founded in 2010.